NASDAQ: FORAForian Inc Stock
$2.25+0.04 (+1.81%)
Updated Sep 22, 2023
FORA Price
$2.25
Fair Value Price
N/A
Market Cap
$73.31M
52 Week Low
$2.00
52 Week High
$5.45
P/E
-20.45x
P/B
3.53x
P/S
3.18x
PEG
N/A
Dividend Yield
N/A
Revenue
$24.84M
Earnings
-$3.31M
Gross Margin
75.5%
Operating Margin
-9.65%
Profit Margin
-13.3%
Debt to Equity
1.66
Operating Cash Flow
-$5M
Beta
0.67
Next Earnings
Nov 13, 2023
Ex-Dividend
N/A
Next Dividend
N/A
FORA Overview
Forian Inc. provides software solutions, proprietary data-driven insights, and predictive analytics to the healthcare, cannabis, and government sectors. The company's products include BioTrack, Cannalytics, BioTrack State Traceability & Enforcement Monitoring System, and STEMS. The company also offers security monitoring and web marketing services. The company is headquartered in Newtown, PA.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how FORA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FORA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
FORA is poor value based on its book value relative to its share price (3.53x), compared to the US Health Information Services industry average (3.08x)
P/B vs Industry Valuation
FORA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more FORA due diligence checks available for Premium users.
Be the first to know about important FORA news, forecast changes, insider trades & much more!
FORA News
Valuation
FORA fair value
Fair Value of FORA stock based on Discounted Cash Flow (DCF)
Price
$2.25
Fair Value
$2.84
Undervalued by
20.66%
FORA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
FORA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-20.45x
Industry
54.73x
Market
14.52x
FORA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.53x
Industry
3.08x
FORA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
FORA's financial health
Profit margin
Revenue
$4.9M
Net Income
-$1.1M
Profit Margin
-22.9%
FORA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
FORA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$55.3M
Liabilities
$34.6M
Debt to equity
1.66
FORA's short-term assets ($55.07M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FORA's short-term assets ($55.07M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FORA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$248.8k
Investing
$2.3M
Financing
-$32.8k
FORA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
FORA vs Health Information Service Stocks
Forian Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.